Table 1.
Input to the Ticagrelor Case Study
| Ticagrelor | Clopidogrel | Δ | |
|---|---|---|---|
| Life years25 | 11.47 | 11.32 | 0.15 |
| QALY25 | 9.66 | 9.53 | 0.13 |
| Total health care costs in SEK25 | 346,803 (£30,935) | 343,560 (£30,646) | 3243 (£289) |
| ICER in SEK/QALY (£/QALY)25 | 25,022 (£2232) | ||
| INHB per patient in QALYa | 0.117 | ||
| INMB per patient in SEK (£)a | 29,257 (£2610) |
ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; INMB, incremental net monetary benefit; QALY, quality-adjusted life year.
a
Based on a threshold of SEK 250,000 (£22,300).